Table 1.

Demographic and Clinical Characteristics of 10 Patients with Multiple Sclerosis Who Experienced Clinical or MRI Exacerbation after Fingolimod Cessation.

	Group I			Group II				Group III
Patient No.	1	2	3	4	5	6	7	8	9	10
Sex	F	F	F	F	M	F	F	F	F	F
At fingolimod initiation
Disease duration (years)	1	4	2	13	37	13	23	3	7	5
ARR (preceding year)	3	2	1	0	1	1	1	0	1	1
Clinical course	RR	RR	RR	SP	RR	SP	SP	mono	RR	RR
EDSS	6.5	1.0	2.5	6.5	2.5	4.5	4.5	0.0	1.5	0.0
During fingolimod therapy
Duration of fingolimod treatment (weeks)	124	264	144	260	248	202	152	120	84	144
ARR	3	0	0	0	0	0	0	0	0	0.36
EDSS	6.5	1.0	2.5	6.5	2.5	4.5	4.5	0.0	1.5	0.0
Age at fingolimod cessation (years)	54	37	36	46	59	44	58	34	45	39
Clinical or MRI exacerbation after fingolimod cessation
Time from fingolimod cessation ( days)	16	98	87	52	42	140	141	36	91	21
EDSS	7.0	1.5	3.5	7.5	2.5	4.5	4.5	0.0	1.5	2.5
Days from fingolimod cessation to DMF initiation	41	n.i.	134	64	43	32	84	35	36	43
Peripheral blood lymphocyte count (/μL)
At fingolimod cessation	530	372	103	90	497	481	326	411	479	368
4 weeks after fingolimod cessation	1,431	499	297	1,468	1,081	979	638	1,209	1,191	718

ARR: annual relapse rate, EDSS: expanded disability status scale, DMF: dimethyl fumarate, MRI: magnetic resonance imaging, RR: relapsing-remitting, SP: secondary progressive, mono: monophasic, n.i.: not induced